We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ZGN:NYSEErmenegildo Zegna N.V. Analysis

Data as of 2026-05-28 - not real-time

$14.41

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Ermenegildo Zegna (ZGN) is trading at $14.41, well above its 30‑day DCF fair value of $9.68 and the 20‑day SMA of $12.77, indicating a price premium despite a modest revenue growth of 0.3%. Technicals remain bullish – the MACD line sits above its signal (0.55 vs 0.45) and the price is above both the 20‑day and 50‑day SMAs, though the RSI of 73 flags an overbought condition. The stock benefits from a recent analyst upgrade to **Buy** by TD Cowen and a raised target by BofA, supported by a solid Q1 sales beat (+7% YoY) driven by Zegna and Tom Ford brands, with China returning to growth.
Fundamentally, ZGN posts strong gross margins (67.5%) and healthy operating cash flow, while maintaining a modest dividend yield of 0.98% with a 31.6% payout ratio, suggesting dividend sustainability. However, the balance sheet shows a high debt‑to‑equity of 89% and a beta of ~1.5, contributing to elevated volatility (≈46% 30‑day) and sector‑specific cyclicality risks. The combination of an overvalued market price, high volatility, and significant debt tempers enthusiasm, positioning the stock as a **hold** in the short term but a **buy** for investors comfortable with medium‑term upside from brand momentum and strategic growth in key markets.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price above fair value and overbought RSI
  • Bullish MACD but decreasing volume trend
  • High short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst upgrades and raised price targets
  • Strong brand execution with Zegna and Tom Ford driving sales
  • Improving demand in China and robust gross margins

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Sustainable dividend supported by cash flow
  • Elevated debt levels and beta indicating higher systematic risk
  • Long‑term brand equity and diversification across luxury segments

Key Metrics & Analysis

Financial Health

Revenue Growth0.30%
Profit Margin5.14%
P/E Ratio32.8
ROE10.52%
ROA3.59%
Debt/Equity89.38
P/B Ratio3.2
Op. Cash Flow$335.6M
Free Cash Flow$246.6M

Technical Analysis

TrendBullish
RSI73.3
Support$11.41
Resistance$14.45
MA 20$12.77
MA 50$11.66
MA 200$10.36
MACDBullish
VolumeDecreasing
Fear & Greed Index92.34

Valuation

Fair Value$9.68
Target Price$13.33
Upside/Downside-7.48%
GradeOvervalued
TypeBlend
Dividend Yield0.98%

Risk Assessment

Beta1.53
Volatility46.40%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.